FTSE MIB
33.523,81 -183,40 (-0,54%) Dow Jones
39.112,16 -299,05 (-0,76%) Nasdaq
17.717,65 +220,84 (+1,26%) Nikkei 225
39.667,07 +493,92 (+1,26%) Petrolio
81,26 +0,43 (+0,53%) Bitcoin EUR
57.494,73 +279,99 (+0,49%)
IMVT Jun 2024 25.000 call
| Chiusura precedente | 1,7800 |
| Aperto | 2,6000 |
| Denaro | 1,2500 |
| Domanda | 3,4000 |
| Prezzo d'esercizio | 25,00 |
| Scadenza | 2024-06-21 |
| Min-Max giorno | 2,6000 - 2,6000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 92 |
- GlobeNewswire
Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares
NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the closing of its previously announced underwritten public offering of 8,475,500 shares of its common stock at a price of $38.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,105,500 additional shares of common stock. Concurrent with the publ
- GlobeNewswire
Immunovant Announces Pricing of $450 Million Common Stock Financing
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten public offering and concurrent private placement, with anticipated gross proceeds to Immunovant of approximately $450 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transactions. All of
- GlobeNewswire
Immunovant Announces Proposed Offering of $300 Million of Common Stock
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the commencement of a proposed underwritten public offering and concurrent private placement of an aggregate of $300,000,000 of shares of its common stock. Immunovant intends to offer and sell $130,000,000 of shares of its common stock in an underwritten public offering. In addition, Immunovant in
